Who Buys Mebendazole from India — 756 Importers Behind a $13.7M Market

The importers of Mebendazole from India can be categorized into several key segments:

1. Distributors: These entities purchase Mebendazole in bulk to supply to various healthcare providers, pharmacies, and retailers within their respective countries. For instance, PLANET PHARMA in France, the top buyer with imports totaling $1.22 million, likely operates as a distributor, ensuring widespread availability of the medication across the nation.

2. Hospital Groups: These are networks of hospitals that procure pharmaceuticals directly to meet the needs of their patients. While specific hospital groups are not explicitly listed among the top buyers, it's common for such organizations to engage in direct procurement to manage costs and ensure a steady supply of essential medicines.

3. Retail Chains: Large pharmacy chains may import Mebendazole to stock their outlets nationwide. However, the provided data does not specify any retail chains among the top buyers.

4. Government Procurement Agencies: These agencies are responsible for acquiring medicines for public health initiatives. CAMEG in Burkina Faso, with imports amounting to $0.30 million, exemplifies this segment, likely procuring Mebendazole for national deworming programs and other public health campaigns.

5. Re-exporters: Companies that import pharmaceuticals with the intent to export them to other markets. The data does not explicitly identify re-exporters among the top buyers.

6. Contract Manufacturers: These are firms that import active pharmaceutical ingredients or bulk drugs to manufacture finished products domestically. The current data does not highlight any contract manufacturers among the leading importers.

Typical buying behaviors and order patterns vary across these segments. Distributors and government procurement agencies often place large, periodic orders to maintain adequate stock levels and meet public health demands. Hospital groups may order based on patient needs and treatment protocols, leading to more consistent but smaller order sizes. Retail chains, if involved, would likely order based on consumer demand and inventory turnover rates.

Understanding the import regulations for Mebendazole in the top importing countries is crucial for market entry and compliance.

The demand for Mebendazole in importing countries is primarily driven by the prevalence of soil-transmitted helminthiases (STH), commonly known as intestinal worm infections. According to the World Health Organization (WHO), over 1.5 billion people, or 24% of the world's population, are infected with STHs, with the highest burden in sub-Saharan Africa, the Americas, China, and East Asia. Mebendazole is listed on the WHO's Model List of Essential Medicines, underscoring its importance in treating these infections.

Government healthcare programs and initiatives significantly contribute to the demand for Mebendazole. Many countries have implemented mass drug administration (MDA) campaigns targeting at-risk populations, particularly school-aged children, to control and eliminate STHs. These programs often involve large-scale procurement of Mebendazole through international tenders and partnerships with organizations like UNICEF and the Global Fund. The inclusion of Mebendazole in national essential medicines lists further facilitates its procurement and distribution, ensuring its availability in public health facilities.

The data from TransData Nexus indicates a diverse buyer landscape, with 756 buyers across 108 countries, reflecting the global recognition of Mebendazole's efficacy and the concerted efforts to combat STHs worldwide.

The importers of Mebendazole from India can be categorized into several key segments:

1. Distributors: These entities purchase Mebendazole in bulk to supply to various healthcare providers, pharmacies, and retailers within their respective countries. For instance, PLANET PHARMA in France, the top buyer with imports totaling $1.22 million, likely operates as a distributor, ensuring widespread availability of the medication across the nation.

2. Hospital Groups: These are networks of hospitals that procure pharmaceuticals directly to meet the needs of their patients. While specific hospital groups are not explicitly listed among the top buyers, it's common for such organizations to engage in direct procurement to manage costs and ensure a steady supply of essential medicines.

3. Retail Chains: Large pharmacy chains may import Mebendazole to stock their outlets nationwide. However, the provided data does not specify any retail chains among the top buyers.

4. Government Procurement Agencies: These agencies are responsible for acquiring medicines for public health initiatives. CAMEG in Burkina Faso, with imports amounting to $0.30 million, exemplifies this segment, likely procuring Mebendazole for national deworming programs and other public health campaigns.

5. Re-exporters: Companies that import pharmaceuticals with the intent to export them to other markets. The data does not explicitly identify re-exporters among the top buyers.

6. Contract Manufacturers: These are firms that import active pharmaceutical ingredients or bulk drugs to manufacture finished products domestically. The current data does not highlight any contract manufacturers among the leading importers.

Typical buying behaviors and order patterns vary across these segments. Distributors and government procurement agencies often place large, periodic orders to maintain adequate stock levels and meet public health demands. Hospital groups may order based on patient needs and treatment protocols, leading to more consistent but smaller order sizes. Retail chains, if involved, would likely order based on consumer demand and inventory turnover rates.

Understanding the import regulations for Mebendazole in the top importing countries is crucial for market entry and compliance.

The demand for Mebendazole in importing countries is primarily driven by the prevalence of soil-transmitted helminthiases (STH), commonly known as intestinal worm infections. According to the World Health Organization (WHO), over 1.5 billion people, or 24% of the world's population, are infected with STHs, with the highest burden in sub-Saharan Africa, the Americas, China, and East Asia. Mebendazole is listed on the WHO's Model List of Essential Medicines, underscoring its importance in treating these infections.

Government healthcare programs and initiatives significantly contribute to the demand for Mebendazole. Many countries have implemented mass drug administration (MDA) campaigns targeting at-risk populations, particularly school-aged children, to control and eliminate STHs. These programs often involve large-scale procurement of Mebendazole through international tenders and partnerships with organizations like UNICEF and the Global Fund. The inclusion of Mebendazole in national essential medicines lists further facilitates its procurement and distribution, ensuring its availability in public health facilities.

The data from TransData Nexus indicates a diverse buyer landscape, with 756 buyers across 108 countries, reflecting the global recognition of Mebendazole's efficacy and the concerted efforts to combat STHs worldwide.